Neoadjuvant chemoimmunotherapy is named as an intervention in 3 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Zhujiang Hospital (1). The most-studied condition is NSCLC Diagnosed by Histology or Cytology.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
NCT07534033 · ClinicalTrials.gov ↗ · NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection
|
Phase 2 | Recruiting | Zhujiang Hospital | China |
|
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
NCT07613567 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Carcinoma
|
Phase 3 | Not yet open | Fujian Cancer Hospital | China |
|
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
NCT07752589 · ClinicalTrials.gov ↗ · Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
|
Observational | Not yet open | Guangdong Provincial People's Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Zhujiang Hospital | 1 |
| Fujian Cancer Hospital | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name Neoadjuvant chemoimmunotherapy as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Zhujiang Hospital (1), Fujian Cancer Hospital (1) and Guangdong Provincial People's Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Neoadjuvant chemoimmunotherapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Neoadjuvant chemoimmunotherapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Neoadjuvant chemoimmunotherapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.